Please wait while the transcript is being prepared...
0:00
Hello, my name is
Tim F. Greten and
I'm a senior investigator in
the United States and
I'm going to talk about
immunotherapy of
hepatocellular carcinoma.
I have received my training back
in Germany and I've been
working in this field
for many years and it's truly
an exciting topic and I'm
excited to give this
presentation to you.
So let's get started. The topic
0:22
has really gained a lot
of interest recently.
If you put into PubMed just
the two terms, hepatocellular
and immune, you
can see the number
of hits in PubMed over time,
basically demonstrating
the relevance and
the significance of this topic.
In addition, there is a
great financial interest.
It is expected the
unresectable HCC market
was valued at approximately
USD 1,487.75 million
in 2021.
By 2027, we expect
this number to go even further
up to USD 2,851 million.
So let's get started
with the science.
1:07
HCC and biliary tumors,
which are both primary
liver cancers,
are actually pretty common
worldwide as well as
in the United States.
In the United States,
it is actually the
number five in terms of
cancer-related deaths in men and
the number seven in women.
1:30
A big problem is that
the 10-year mortality
trend has not really
changed in the past years
for liver and intrahepatic
bile duct cancer,
indicating the big need to
advance new treatments.
